Document is current
Any future updates will be listed below
-
Authors
Handa, James T.
Bowes Rickman, Cathy
Dick, Andrew D.
Gorin, Michael B. http://orcid.org/0000-0001-9498-7982
Miller, Joan W. http://orcid.org/0000-0003-2046-3996
Toth, Cynthia A.
Ueffing, Marius
Zarbin, Marco
Farrer, Lindsay A.
-
Funding
Funding for this research was provided by:
BrightFocus Foundation
American Macular Degeneration Foundation
Research to Prevent Blindness (Catalyst Award)
U.S. Department of Health & Human Services | National Institutes of Health (EY027691)
Wilmer-Bayer Alliance Grant, Bayer Pharmaceuticals, Inc
International Retinal Research Foundation
Rosetrees Trust
EC | Horizon 2020 Framework Programme
- License Information
-
More Information
Article History
Received: 31 July 2018
Accepted: 3 July 2019
First Online: 26 July 2019
Competing interests
: J.T.H.: Grant funding from Bayer Pharmaceuticals, Inc. J.W.M.: Consultant/Advisor for Genentech/Roche, Bausch+Lomb, Kalvista Pharmaceuticals, ONL Therapeutics; Grant Support from Lowy Medical Research Institute; Equity in ONL Therapeutics; Patents/Royalties from ONL Therapeutics/Mass. Eye and Ear, Valeant Pharmaceuticals/Mass. Eye and Ear. C.A.T.: Alcon royalties for surgical technologies. M.Z.: Cell Cure, Chengdu Kanghong Biotech, Coherus Biosciences, Daiichi Sankyo, Frequency Therapeutics, Healios KK, Iridex, Isarna Therapeutics, Genentech/Roche, Makindus, Novartis Pharma AG, Ophthotech, Percept Corp., Rutgers University (patent). The remaining authors declare no competing interests.
